Research Suggests Dementia Epidemic Overplayed: Should Companies Rethink Strategy?
This article was originally published in Scrip
Contrary to expectations of a "dementia epidemic", a new study has found that the number of cases in some western European countries seems to be stabilizing, if not decreasing, thanks to better living standards and management of vascular and chronic diseases. Companies investing in expensive and elusive dementia breakthroughs may be disheartened to hear the review's lead author caution against "the current overemphasis on diagnostics and drug interventions".
You may also be interested in...
Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.